ImmuPharma PLC is a pharmaceutical development company listed since 2006 on AIM of the London Stock Exchange. The company is focusing on developing novel medicines with high sales potential in specialist markets with serious unmet need. ImmuPharma has five drug candidates in development, two platform technologies and approximately 70 patents. Lupuzor ™ is the company’s most advanced drug candidate and is a treatment for lupus, and life threatening auto immune disease. Lupuzor ™ has 'Gold Standard' approval from the US FDA for its Phase III trial with a Special Protocol Assessment and "Fast Track" designation. Lupuzor ™ has now commenced its Phase III pivotal trial.

London, GB
Size (employees)
10 (est)
Immupharma is headquartered in London, GB

Immupharma Office Locations

Immupharma has offices in London, Mulhouse and Sarnen
London, GB (HQ)
50 Broadway
Sarnen, CH
10 Poststrasse
Mulhouse, FR
5 Rue Du Rhône

Immupharma Metrics

Immupharma Financial Metrics

Revenue (2015)

£76.4 k

Revenue growth (2014-15), %


Market capitalization (28-Apr-2017)

£61 m

Closing share price (28-Apr-2017)

Immupharma's current market capitalization is £61 m.
Immupharma's revenue was reported to be £76.4 k in FY, 2015 which is a 59% decrease from the previous period.
FY, 2014FY, 2015


£184.8 k£76.4 k

Revenue growth, %


Immupharma Market Value History

Immupharma Online Presence

Immupharma Company Life

You may also be interested in